Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant
Open Access
- 28 August 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 5 (10) , 1755-1766
Abstract
Complications of cirrhosis and portal hypertension (PH) can be reduced by statin therapy. The common loss-of-function variant p.V174A in the solute carrier organic anion transporter gene 1B1 (SLCO1B1) gene encoding the organic anion transporting polypeptide 1B1 results in decreased hepatic uptake of statins. Our specific aim was to assess the impact of this variant in patients with cirrhosis and statin treatment while controlling for the stage of cirrhosis and other potential confounders with propensity score matching (PSM), availing of a large cohort of genotyped study patients. In total, from 1,088 patients with cirrhosis in two German academic medical centers, PSM yielded 154 patients taking statins and 154 matched controls. The effect on PH was assessed by the liver stiffness–spleen size–to–platelet score (LSPS), and complications of cirrhosis were retrospectively recorded applying consensus criteria. As hypothesized, patients on statin treatment presented less frequently with signs of PH: Esophageal varices (41% vs. 62%; P < 0.001) were less common, and LSPS (4.8 ± 11.5 vs. 5.6 ± 6.4; P = 0.01) was reduced. Correspondingly, decompensation events were also reduced in patients on statins (odds ratio [OR] = 0.54, 95% confidence interval [CI] 0.32-0.90; P = 0.02). When the variant in SLCO1B1 was present in patients on statins, esophageal varices (OR = 2.68, 95% CI 1.24-5.81; P = 0.01) and bacterial infections (OR = 2.50, 95% CI 1.14-5.47; P = 0.02) were more common as compared with wild type carriers on statins. Conclusion: In this cohort, signs and complications of PH were reduced in patients with cirrhosis treated with statins. Notably, this effect was diminished by the common loss-of-function variant in SLCO1B1. Further prospective studies in independent cohorts are warranted to confirm these genotype-specific observations.Keywords
This publication has 40 references indexed in Scilit:
- Impact ofSLCO1B1(OATP1B1) andABCG2(BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statinsXenobiotica, 2011
- Methotrexate Pharmacokinetics in Transgenic Mice with Liver-Specific Expression of Human Organic Anion-Transporting Polypeptide 1B1 (SLCO1B1)Drug Metabolism and Disposition, 2009
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyNew England Journal of Medicine, 2008
- Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthaseHepatology, 2007
- Statins and the Risk of Pneumonia: A Population‐Based, Nested Case‐Control StudyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
- SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenetics and Genomics, 2006
- Variable Selection for Propensity Score ModelsAmerican Journal of Epidemiology, 2006
- Statin use and mortality within 180 days after bacteremia: A population-based cohort study*Critical Care Medicine, 2006
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006
- Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosisGastroenterology, 2004